Your browser doesn't support javascript.
loading
The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status.
Ashford, Miriam T; Veitch, Dallas P; Neuhaus, John; Nosheny, Rachel L; Tosun, Duygu; Weiner, Michael W.
Afiliação
  • Ashford MT; Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education, San Francisco, California, USA.
  • Veitch DP; Department of Veterans Affairs Medical Center, Center for Imaging and Neurodegenerative Diseases, San Francisco, California, USA.
  • Neuhaus J; Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education, San Francisco, California, USA.
  • Nosheny RL; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
  • Tosun D; Department of Veterans Affairs Medical Center, Center for Imaging and Neurodegenerative Diseases, San Francisco, California, USA.
  • Weiner MW; Department of Psychiatry, University of California San Francisco, San Francisco, California, USA.
Alzheimers Dement ; 17(5): 866-887, 2021 05.
Article em En | MEDLINE | ID: mdl-33583100
ABSTRACT

INTRODUCTION:

Convenient, cost-effective tests for amyloid beta (Aß) are needed to identify those at higher risk for developing Alzheimer's disease (AD). This systematic review evaluates recent models that predict dichotomous Aß. (PROSPERO CRD42020144734).

METHODS:

We searched Embase and identified 73 studies from 29,581 for review. We assessed study quality using established tools, extracted information, and reported results narratively.

RESULTS:

We identified few high-quality studies due to concerns about Aß determination and analytical issues. The most promising convenient, inexpensive classifiers consist of age, apolipoprotein E genotype, cognitive measures, and/or plasma Aß. Plasma Aß may be sufficient if pre-analytical variables are standardized and scalable assays developed. Some models lowered costs associated with clinical trial recruitment or clinical screening.

DISCUSSION:

Conclusions about models are difficult due to study heterogeneity and quality. Promising prediction models used demographic, cognitive/neuropsychological, imaging, and plasmameasures. Further studies using standardized Aß determination, and improved model validation are required.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Biomarcadores / Valor Preditivo dos Testes / Peptídeos beta-Amiloides / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Biomarcadores / Valor Preditivo dos Testes / Peptídeos beta-Amiloides / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos